Founder Ousted as CEO; IM Cannabis Names Zalayet to Lead Tech Pivot
IMCC sits 22% above its 52-week low of $0.41.
Summary
Founder Oren Shuster resigned as CEO effective November 19, 2026, and the board appointed Ronen Zalayet as chief executive officer to succeed him; the company said the resignation was not related to any disagreement with it on any matter relating to its operations, policies or practices. Oren Shuster also resigned as a director of the company effective the same date and will continue to serve as a director of the company's Israeli subsidiaries. Zalayet is a career CFO whose background is finance and accounting rather than cannabis operations. Shakked Shuster became CEO of Focus Medical Herbs, the Israeli medical cannabis subsidiary, succeeding Oren Shuster. Ohad Melnik was appointed to the board effective November 19, 2026, filling the vacancy created by Einat Zakariya's resignation in September 2026, and the board determined he is an independent director under Nasdaq listing rules; his appointment is subject to Israel Medical Cannabis Agency approval. The company frames the shakeup as aligning with its stated push into technology-driven businesses beyond medical cannabis, which follows the September non-binding deal for a 51% stake in Space Defense Innovations. Context matters here: Q3 revenue fell 68% year over year to C$1.65M with a small gross loss, and the company has stacked a $1.2M convertible note, a $1.31M discounted offering, and resale registrations covering multiples of its share count. A 1-for-3 reverse split takes effect November 23, 2026, with shares currently around $0.50 pre-split. The leadership change is real but the thesis hinges on whether the new CEO can fund the pivot without more dilution.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — Shakked Shuster became CEO of subsidiary Focus Medical Herbs, succeeding Oren Shuster; Ohad Melnik's board appointment is subject to Israel Medical Cannabis Agency approval.
- CEO Transition — Effective November 19, 2026, Ronen Zalayet became CEO, succeeding Oren Shuster, who resigned from that role and as a director and will continue to serve as a director of the Israeli subsidiaries.
- Resignation Terms — Oren Shuster's resignation was not related to any disagreement with the company on any matter relating to its operations, policies or practices.
- Board Appointment — Effective November 19, 2026, Ohad Melnik was appointed to the Board, filling the vacancy created by Einat Zakariya's September 2026 resignation; the Board determined he is independent under Nasdaq listing rules.
All 5 details
- Effective November 19, 2026, Oren Shuster resigned as a director of the Company and will continue to serve as a director of the Company's Israeli subsidiaries.
- Mr. Shuster's resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
- Effective November 19, 2026, the Board appointed Ronen Zalayet as Chief Executive Officer of the Company, succeeding Oren Shuster, who resigned from that role.
- Effective November 19, 2026, Ohad Melnik was appointed to the Board to fill the vacancy created by the resignation of Einat Zakariya in September 2026.
- The Board has determined that Mr. Melnik is an independent director under the Nasdaq listing rules.
At the time of this announcement, IMCC was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $859.7K. The 52-week trading range was $0.41 to $62.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.